世界のヒヨスチン市場の規模、シェア、トレンド分析レポート – 業界の概要と2031年までの予測

ヒヨスチン市場分析

世界のヒヨスチン市場は、胃腸障害、乗り物酔い、その他さまざまな病状の治療への応用が増えていることから、大幅な成長が見込まれています。研究によると、この薬は鎮痙作用があり、過敏性腸症候群 (IBS) や消化性潰瘍などの病状に苦しむ患者に特に有効です。市場の拡大は、医療費の増加、胃腸の健康に対する意識の高まり、消化器系の問題を抱えやすい高齢化人口の増加によってさらに後押しされています。さらに、胃に優しいカプセルや併用療法の開発など、薬剤処方の進歩により、ヒヨスチンベースの製品の有効性と患者のコンプライアンスが向上しています。世界的に市販薬 (OTC) への傾向が強まっているため、処方箋なしで購入できる薬の選択肢に対する需要の高まりに対応し、ヒヨスチンの入手しやすさが向上することが期待されています。全体として、ヒヨスチン市場は、継続的な研究、革新的な製品の提供、そして胃腸の健康管理に対する消費者の関心の高まりに支えられ、繁栄する可能性が高いと考えられます。

ヒヨスチン市場規模

世界のヒヨスチン市場規模は、2023年に4億1,333万米ドルと評価され、2024年から2031年の予測期間中に3.80%のCAGRで成長し、2031年には5億5,702万米ドルに達すると予測されています。市場価値、成長率、セグメンテーション、地理的範囲、主要プレーヤーなどの市場シナリオに関する洞察に加えて、Data Bridge Market Researchがまとめた市場レポートには、詳細な専門家の分析、患者の疫学、パイプライン分析、価格分析、規制の枠組みも含まれています。

ヒヨスチン市場の動向

「併用療法の需要増加」

The global hyoscine market is experiencing significant growth, particularly due to the rising prevalence of gastrointestinal disorders such as irritable bowel syndrome (IBS) and motion sickness. One notable trend is the increasing demand for combination therapies that enhance the effectiveness of hyoscine. For instance, products such as BuscoMint, which combines hyoscine butylbromide with peppermint oil, are gaining popularity for their synergistic effects in alleviating abdominal discomfort and cramps. This trend is driven by consumers seeking more holistic approaches to managing their symptoms, thereby improving patient adherence and outcomes. Furthermore, the rise of over-the-counter (OTC) medications has made hyoscine more accessible, allowing individuals to manage conditions such as nausea and gastrointestinal spasms without a prescription. As healthcare providers continue to recommend hyoscine-based products for symptomatic relief, the market is expected to expand further, fueled by innovation and increasing awareness of digestive health.

Report Scope and Hyoscine Market Segmentation    

Hyoscine Market Definition

Hyoscine, also known as scopolamine, is an anticholinergic medication commonly used to treat various conditions, including motion sickness, abdominal cramping, and nausea. It works by blocking the action of acetylcholine, a neurotransmitter involved in muscle movement and the regulation of bodily functions.  Its efficacy in alleviating symptoms associated with gastrointestinal disorders and motion sickness has made it a valuable option in clinical practice.

Hyoscine Market Dynamics

Drivers

• Increasing Prevalence Gastrointestinal Disorders

The increasing prevalence of gastrointestinal disorders is a significant driver for the hyoscine market. For instance, the global prevalence of irritable bowel syndrome (IBS) ranges between 10% to 15% of the population, with studies indicating that nearly 1 in 7 adults in the U.S. suffers from this condition. Additionally, motion sickness affects approximately 30% to 40% of the population, particularly in children and pregnant women. As awareness of these conditions grows and more individuals seek effective treatments, the demand for hyoscine-based medications is expected to rise. This trend highlights the importance of addressing gastrointestinal disorders through targeted pharmaceutical interventions, including hyoscine, which is effective in alleviating symptoms associated with these conditions.

• Growing Awareness and Acceptance of Anticholinergic Drugs

The growing awareness and acceptance of anticholinergic drugs, including hyoscine, significantly contribute to the expansion of the hyoscine market. Anticholinergics have been widely recognized for their effectiveness in managing symptoms of nausea and vomiting, particularly in contexts such as postoperative care and motion sickness. A study published in the British Journal of Anaesthesia found that the use of anticholinergic drugs, including hyoscine, resulted in a significant reduction in postoperative nausea and vomiting in patients undergoing surgery. This increasing recognition among healthcare professionals and patients has led to a higher demand for hyoscine, particularly in surgical settings and for individuals prone to motion sickness, thereby driving market growth and acceptance of these medications as essential treatment options.

Opportunities

• Increasing Technological Advancements in Drug Delivery Systems

Technological advancements in drug delivery devices, particularly through the use of nanotechnology and sustained-release formulations, are significantly enhancing the efficacy and patient compliance of hyoscine treatments. For instance, nanoparticles can be engineered to deliver hyoscine directly to target tissues, minimizing side effects and optimizing therapeutic effects. For instance, the development of Hyoscine-Loaded nanocarriers that allow for controlled release, which can maintain therapeutic levels of the drug in the bloodstream over extended periods, thereby reducing the frequency of dosing and improving patient adherence to treatment regimens. This leads to better health outcomes and opens new market opportunities for pharmaceutical companies to differentiate their products in a competitive landscape. By investing in these advanced delivery systems, companies can meet the growing demand for more effective and patient-friendly medications, thus expanding their market reach and enhancing their competitive edge.

• Rising Research and Development (R&D) Expenditure

Continuous investments in research and development (R&D) for new formulations and delivery methods are crucial for enhancing the efficacy and safety profile of hyoscine, ultimately driving market growth. For instance, the development of long-acting formulations of hyoscine, such as extended-release tablets or injectable forms, can provide prolonged relief from symptoms such as motion sickness or gastrointestinal spasms, reducing the need for frequent dosing. A recent innovation in this area includes the formulation of a long-acting hyoscine transdermal patch that releases the medication gradually over several days, significantly improving patient compliance and satisfaction. Furthermore, the exploration of combination products, which integrate hyoscine with other therapeutic agents to target multiple symptoms or conditions simultaneously, offers additional avenues for differentiation in the market. These innovations meet the growing consumer demand for more effective and convenient treatment options and present substantial opportunities for pharmaceutical companies to expand their product portfolios and capture larger market shares in the competitive landscape of gastrointestinal and motion sickness therapies.

Restraints/Challenges

• Stringent Regulations and Extensive Clinical Trials

Regulatory hurdles represent a significant challenge in the hyoscine market, as the pharmaceutical industry operates under stringent guidelines that govern the approval of new formulations and delivery methods. The process of obtaining regulatory approval can be lengthy and costly, often requiring extensive clinical trials to demonstrate safety and efficacy. For instance, when developing a new extended-release formulation of hyoscine, a company may need to conduct multiple phases of clinical studies, which can take several years and involve substantial financial investment. Delays in these approvals can hinder timely product launches, allowing competitors to gain market share with established formulations. Furthermore, stringent regulations may deter new entrants from exploring opportunities in the hyoscine market, as the high costs and risks associated with compliance can be prohibitive. This regulatory landscape affects the speed of innovation and limits the diversity of products available to consumers, ultimately impacting the overall growth of the hyoscine market.

• Side Effects and Safety Concerns

Side effects and safety concerns pose a significant challenge for the hyoscine market, as adverse reactions can deter patients from using the medication and impact adherence to treatment regimens. While hyoscine is effective in managing conditions such as motion sickness and gastrointestinal spasms, common side effects include dry mouth, dizziness, and blurred vision, which can significantly affect a patient's quality of life. Additionally, safety concerns surrounding the long-term use of hyoscine, particularly in vulnerable populations such as the elderly, can further limit its acceptance among healthcare providers. As a result, hampering the overall development of the market.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Hyoscine Market Scope

The market is segmented on the basis of drug type, application, route of administration, mode of purchase, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Type

• Hyoscine Butyl Bromide
• Hyoscine Hydrobromide

Application

• Motion Sickness
• Cramps
• Nausea

Route of Administration

• Intravenous
• Oral
• Patches

Mode of Purchase

• Prescription
• Over the Counter

Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Hyoscine Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, drug type, application, route of administration, mode of purchase, and distribution channel as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is projected to dominate the market share, primarily driven by a growing geriatric population that requires effective treatments for various health issues, including motion sickness. Increased public awareness regarding the symptoms and preventive measures for motion sickness further fuels demand for relevant medications. Additionally, the region boasts a strong presence of pharmaceutical companies engaged in drug manufacturing, which enhances the availability of these products. Furthermore, the rise in hospital admissions and surgical procedures contributes to a greater need for motion sickness treatments, solidifying North America's leading position in this market.

Asia Pacific, alongside Europe, is anticipated to emerge as the fastest-growing market, driven by the establishment of numerous new healthcare centers that enhance access to medical services. This expansion is supported by increased healthcare budgets, which allow for the development of advanced facilities and better patient care. Additionally, growing investments in healthcare infrastructure and technology further bolster the market's growth potential. As a result, these regions are poised to witness significant advancements in healthcare delivery and rehabilitation solutions, meeting the rising demand for effective treatments.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

ヒヨスチンの市場シェア

市場競争環境では、競合他社ごとの詳細が提供されます。詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、世界的なプレゼンス、生産拠点と施設、生産能力、会社の強みと弱み、製品の発売、製品の幅と広さ、アプリケーションの優位性などが含まれます。提供される上記のデータ ポイントは、市場に関連する会社の焦点にのみ関連しています。

市場で活動しているヒヨスチンのマーケットリーダーは次のとおりです。

• アルカロイドコーポレーション（米国）
• バクスター（米国）
• カレブ・ファーマシューティカルズ社（米国）
• GSK plc（英国）
• C2ファーマ（ドイツ）
• ミョンムン製薬株式会社（韓国）
• LINNEA SA（スイス）
• ペリゴ カンパニー plc (アイルランド)
• ベーリンガーインゲルハイムインターナショナルGmbH（ドイツ）
• 広州漢方製薬有限公司（中国）
• セントロフローラ（ブラジル）
• アルケムインターナショナル株式会社（インド）
• ノバルティスAG（スイス）

ヒヨスチン市場の最新動向

• 2024年8月、インドのバイエル社コンシューマーヘルス部門の有名な鎮痛剤ブランドであるサリドンは、生理痛に特化した先駆的なソリューション「サリドン ウーマン」を発売しました。この革新的な製品は、腹部のけいれん、腰痛、頭痛など、一般的な生理の不快感を総合的に緩和します。サリドン ウーマンは、市販薬分野における大きな進歩であり、生理痛に対処するためにパラセタモールの有効性と植物由来の化合物ヒオスシンブチル臭化物を独自に組み合わせています。
• 2023年9月、ディフェンダー・ファーマシューティカルズは、食品医薬品局（FDA）がスコポラミン（別名ヒオスシン）の鼻腔内製剤であるDPI-386鼻腔用ジェルの新薬申請に優先審査のステータスを付与したことを発表しました。このジェルは乗り物酔いの予防治療を目的としており、患者にとってより便利な選択肢となる可能性があります。
• 2022年9月、インド連邦保健家族福祉大臣は、ヒオスシンブチル臭化物が2022年国家必須医薬品リストに含まれたことを明らかにした。このリストには、27の異なるグループに分類された384の医薬品が含まれている。この認定は、さまざまな病状の管理におけるこの薬の重要性を強調し、国全体で医療へのアクセスを向上させる役割を強調している。
• サノフィは2020年12月、過敏性腸症候群（IBS）の治療薬として、BuscoMintペパーミントオイル0.2mlカプセルを発売した。メーカーによると、この胃に優しいカプセルは、特にIBSに苦しむ人の腹部の不快感、膨満感やけいれんを和らげるという。カプセル1個あたり、ペパーミントティー約67杯分に相当するペパーミントオイル0.2mlと、ヒオスシンブチルブロミドが含まれている。

SKU-60423